Therapeutic Drug Monitoring in Oncology: IATDMCT Recommendations for 5-Fluorouracil Therapy

Beumer JH, Chu E, Allegra C, et al. Clin Pharmacol Ther. 2019;105(3):598-613.

Patient care evolves around evidence based guidelines. An expert working committee of clinician-scientists tasked by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology reviewed the available peer-reviewed literature.

TDM of 5-FU was strongly recommended for dose titration. The required evidence is: established therapeutic ranges, demonstrated improved action and/or lower toxicity in controlled TDM clinical trials. The clinical outcome is: therapeutic blood levels give the highest probability of response, “subtherapeutic” levels have the risk of lower response rates, “supratherapeutic” levels increase the risk of toxicity.

Start typing and press Enter to search